KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Jan 30, 2026 >>  ABB India 5576.9  [ 1.84% ]  ACC 1637.5  [ -2.40% ]  Ambuja Cements 510.2  [ -4.81% ]  Asian Paints 2428.65  [ 0.49% ]  Axis Bank 1370.25  [ 0.43% ]  Bajaj Auto 9592.9  [ 0.90% ]  Bank of Baroda 299.35  [ -1.04% ]  Bharti Airtel 1968.1  [ 0.00% ]  Bharat Heavy 262.85  [ 0.94% ]  Bharat Petroleum 364  [ -0.79% ]  Britannia Industries 5856.1  [ 2.28% ]  Cipla 1323.95  [ 0.27% ]  Coal India 440.4  [ -3.40% ]  Colgate Palm 2113.6  [ 0.08% ]  Dabur India 506.85  [ -0.34% ]  DLF 635.2  [ -0.49% ]  Dr. Reddy's Labs 1218.4  [ 0.82% ]  GAIL (India) 167.15  [ -0.09% ]  Grasim Industries 2818.95  [ -0.49% ]  HCL Technologies 1694.45  [ -1.55% ]  HDFC Bank 929.35  [ -0.67% ]  Hero MotoCorp 5534.95  [ -0.75% ]  Hindustan Unilever 2373.65  [ 0.94% ]  Hindalco Industries 962.1  [ -6.12% ]  ICICI Bank 1355.05  [ -2.10% ]  Indian Hotels Co. 674.5  [ 1.49% ]  IndusInd Bank 895.35  [ -0.31% ]  Infosys 1640.45  [ -1.04% ]  ITC 322.2  [ 1.11% ]  Jindal Steel 1130.7  [ -2.12% ]  Kotak Mahindra Bank 408  [ -1.05% ]  L&T 3933.45  [ 0.03% ]  Lupin 2151.05  [ 0.90% ]  Mahi. & Mahi 3432.2  [ 1.38% ]  Maruti Suzuki India 14601.55  [ 0.70% ]  MTNL 33.98  [ 10.29% ]  Nestle India 1331.45  [ 3.39% ]  NIIT 74.88  [ -1.34% ]  NMDC 81.15  [ -4.19% ]  NTPC 355.8  [ -0.64% ]  ONGC 268.95  [ -2.29% ]  Punj. NationlBak 125.2  [ 0.00% ]  Power Grid Corpo 256.35  [ -1.61% ]  Reliance Industries 1395.9  [ 0.29% ]  SBI 1077.55  [ 1.23% ]  Vedanta 682.7  [ -10.89% ]  Shipping Corpn. 225.5  [ 1.42% ]  Sun Pharmaceutical 1595  [ 0.36% ]  Tata Chemicals 746.3  [ 3.16% ]  Tata Consumer Produc 1133.9  [ 2.50% ]  Tata Motors Passenge 349.95  [ -0.54% ]  Tata Steel 193.1  [ -4.57% ]  Tata Power Co. 366.6  [ 0.05% ]  Tata Consultancy 3125.05  [ -0.67% ]  Tech Mahindra 1743.3  [ -1.39% ]  UltraTech Cement 12700.05  [ -0.15% ]  United Spirits 1363.35  [ 2.44% ]  Wipro 236.7  [ -1.31% ]  Zee Entertainment En 84.26  [ 1.54% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

MANKIND PHARMA LTD.

30 January 2026 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE634S01028 BSE Code / NSE Code 543904 / MANKIND Book Value (Rs.) 370.30 Face Value 1.00
Bookclosure 08/08/2025 52Week High 2717 EPS 48.23 P/E 44.04
Market Cap. 87679.80 Cr. 52Week Low 2059 P/BV / Div Yield (%) 5.74 / 0.00 Market Lot 1.00
Security Type Other

History of Company

The company history sections lists out major chronological events that happened to the company.
The Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of the Company to a public limited company and as approved by the Shareholders pursuant to a special resolution dated July 14, 2005 the name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.

Major events and milestones:

2004 
-Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar' tablets amongst others

2005 
-Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh
-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others

2007 
-Entered the consumer healthcare segment with the launch of `Manforce' brand
-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised Rs.720 million from Monet Limited

2009 
-Set up the manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh

2010 
-Launched `Preganews' brand in the consumer healthcare segment

2012 
-Setup the first R&D centre at IMT Manesar, Haryana

2014 
-Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)
-Set up the manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh

2015 
-Incorporated the Subsidiary, Lifestar Pharma LLC in the US
-Incorporated the Subsidiary, Mankind Pharma Pte. Limited in Singapore

2017 
-Set up the manufacturing facility in Sikkim

2018 
-The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time

2019 
-Entered the female infertility segment with the launch of `Dydroboon' tablets

2020 
-Incorporated the Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal
-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets
-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets

2021 
-Incorporated the Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE
-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets
-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets

2022 
-Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited
-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others
-Entered into oncology segment with the launch of `Pacliall' injection amongst others
-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories
-The Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited.

2023
-Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.
-Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.
-Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.

2024
-Mankind Pharma Completes Landmark Acquisition of BSV.
-Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.
-Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.
-Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain).

2025
-The Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited  and Jaspack Industries Private Limited  with Mankind Pharma Limited